🇺🇸 FDA

Company profile · Sponsor

PRECISION

PRECISION BIOSCIENCES INC

DTIL · NYSE biotech DURHAM, NC, USA
Pipeline
24
Drugs
5
Patents
8

Quick answer

PRECISION (DTIL) is a biotech company. headquartered in DURHAM, NC, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 5 drugs, and 8 patents to this profile..

Company facts

Ticker DTIL
Exchange NYSE
Company type biotech
Headquarters DURHAM, NC, USA
SEC CIK 0001357874

Pipeline (24)

Search pipeline →

  1. 1.0mg/kg/day PRAX-562

    PRECISION

    Developmental and Epileptic Encephalopathy 1

    phase 3 small molecule active

    1 trial

  2. 18F fluciclovine

    PRECISION

    Brain Metastases

    phase 3 small molecule completed

    2 trials

  3. 1mg elsunersen

    PRECISION

    Epileptic Encephalopathy

    phase 3 small molecule active

    1 trial

  4. 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks

    PRECISION

    Focal Seizure

    phase 3 small molecule active

    1 trial

  5. 40 mg/day vormatrogine for 12 weeks

    PRECISION

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  6. 60 mg ulixacaltamide

    PRECISION

    Essential Tremor

    phase 3 small molecule active

    1 trial

  7. Early Vasopressin

    PRECISION

    Septic Shock

    phase 3 small molecule active

    1 trial

  8. ICT-107

    PRECISION

    Glioblastoma Multiforme

    phase 3 mab completed

    2 trials

  9. PRAX-114

    PRECISION

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  10. PRAX-222

    PRECISION

    Voltage-gated sodium channel type II alpha subunit (SCN2A) developmental and epileptic encephalopathy (DEE)

    phase 3 small molecule active

    1 trial

  11. PRAX-562

    PRECISION

    SCN2A Encephalopathy

    phase 3 small molecule active

    1 trial

  12. PRAX-628, PRAX-628, PRAX-628, PRAX-628

    PRECISION

    Focal onset seizures or primary generalized tonic-clonic seizures.

    phase 3 small molecule active

    1 trial

  13. PRAX-628, PRAX-628, Placebo for PRAX-628, PRAX-628

    PRECISION

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  14. Placebo for PRAX-628, PRAX-628

    PRECISION

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  15. vormatrogine

    PRECISION

    Epilepsy, Tonic-Clonic

    phase 3 small molecule active

    1 trial

  16. 10 mg PRAX-114

    PRECISION

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  17. 10 mg PRAX-114, 20 mg PRAX-114, and Placebo

    PRECISION

    Essential Tremor

    phase 2 small molecule terminated

    1 trial

  18. 100 mg PRAX-944

    PRECISION

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  19. 30mg PRAX-628

    PRECISION

    Focal Onset Seizure

    phase 2 small molecule active

    1 trial

  20. 60 mg PRAX-114 or 40 mg PRAX-114

    PRECISION

    Post-traumatic Stress Disorder

    phase 2 small molecule terminated

    1 trial

  21. Atorvastatin Oral Tablet

    PRECISION

    Mild Cognitive Impairment

    phase 2 small molecule active

    1 trial

  22. BCMA CAR-T cells

    PRECISION

    Multiple Myeloma

    phase 2 mab active

    2 trials

  23. BCMA targeted prime CAR-T cells

    PRECISION

    Multiple Myeloma

    phase 2 mab active

    1 trial

  24. CD123 CAR-T cells

    PRECISION

    Leukemia

    phase 2 mab active

    2 trials

Drugs (5)

Search drugs →

  1. ammonia n-13

    AMMONIA N 13

    INTRAVENOUS approved

  2. fludeoxyglucose f-18

    FLUDEOXYGLUCOSE F18

    INJECTION approved

  3. hydrocortisone butyrate

    HYDROCORTISONE BUTYRATE

    TOPICAL approved

  4. phentolamine mesylate

    PHENTOLAMINE MESYLATE

    OPHTHALMIC approved

  5. sodium fluoride f-18

    SODIUM FLUORIDE F-18

    INTRAVENOUS approved

Patents (8)

Search patents →

  1. US 12419920

    Bifidobacterium longum NCIMB 41676

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12410418

    Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12351839

    Rationally-designed single-chain meganucleases with non-palindromic recognition sequences

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12344676

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12336835

    Neuromodulation to target glucose transporter and/or incretin pathways

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12232492

    Disinfection of bacteriophages products using supercritical carbon dioxide

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12233135

    Therapeutic constructs for treating cancer

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12180463

    Lactobacillus reuteri

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is PRECISION?

PRECISION (DTIL) is a biotech company. headquartered in DURHAM, NC, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 5 drugs, and 8 patents to this profile..

What pipeline programs does PRECISION sponsor?

We track 24 ClinicalTrials.gov-linked programs for PRECISION, including 1.0mg/kg/day PRAX-562 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does PRECISION company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.